First review cycle
This article was originally published in The Gray Sheet
Executive Summary
FDA is considering how product review can be reformed and made "more efficient and less painful for the industry," FDA Deputy Commissioner Lester Crawford reports March 20 at the AdvaMed annual meeting. The agency "will be having some committee meetings and also some public meetings" to gather ideas, he noted...
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.